Skip to main content
. Author manuscript; available in PMC: 2014 Feb 12.
Published in final edited form as: Leukemia. 2009 Nov 12;24(1):22–32. doi: 10.1038/leu.2009.236

Figure 4.

Figure 4

Disruption of plasma cell–microenvironment interactions by immunomodulatory drugs. Anti-myeloma activity is mediated via downregulation of adhesion molecules, cytokine modulation, anti-angiogenesis, anti-osteoclastogenesis, as well as having direct anti-proliferative effects on malignant plasma cells.